Cardiovascular Effects of Tyrosine Kinase Inhibitors Used for Gastrointestinal Stromal Tumors

Hematology/Oncology Clinics of North America

Volumn 23, Issue 1, 2009, Pages 97-107

  Chintalgattu, Vishnu ^a   Patel, Shalin S ^a   Khakoo, Aarif Y ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer; Cardiotoxicity; Gastrointestinal stromal tumor; Imatinib; Sunitinib; Tyrosine kinase inhibitors

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CEDIRANIB; DOXORUBICIN; IMATINIB; MASATINIB; MIDOSTAURIN; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VATALANIB;

CARDIOTOXICITY; CARDIOVASCULAR RISK; DRUG EFFECT; GASTROINTESTINAL TUMOR; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SIDE EFFECT; SUDDEN DEATH; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTHRACYCLINES; CARDIOVASCULAR DISEASES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PROTEIN KINASE INHIBITORS;

EID: 60749118956     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2008.11.004     Document Type: Review

References (61)

1. Benjamin R.S., Wiernik P.H., and Bachur N.R. Adriamycin: a new effective agent in the therapy of disseminated sarcomas. Med Pediatr Oncol 1 1 (1975) 63-76
2. Lefrak E.A., Pitha J., Rosenheim S., et al. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 32 2 (1973) 302-314
3. Schwartz R.G., McKenzie W.B., Alexander J., et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 82 6 (1987) 1109-1118
4. O'Brien M.E., Wigler N., Inbar M., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15 3 (2004) 440-449
5. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342 15 (2000) 1077-1084
6. Oeffinger K.C., Mertens A.C., Sklar C.A., et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355 15 (2006) 1572-1582
7. Schultz-Hector S., and Trott K.R. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data?. Int J Radiat Oncol Biol Phys 67 1 (2007) 10-18
8. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 9544 (2006) 1329-1338
9. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
10. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 2 (2007) 115-124
11. Sherbenou D.W., and Druker B.J. Applying the discovery of the Philadelphia chromosome. J Clin Invest 117 8 (2007) 2067-2074
12. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
13. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 23 (2006) 2408-2417
14. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 14 (2001) 1031-1037
15. Force T., Krause D.S., and Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7 5 (2007) 332-344
16. Saglio G., Morotti A., Mattioli G., et al. Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia. Ann N Y Acad Sci 1028 (2004) 423-431
17. Hynes N.E., and Stern D.F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198 2-3 (1994) 165-184
18. Sparano J.A. Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin Oncol 28 1 Suppl 3 (2001) 20-27
19. Crone S.A., Zhao Y.Y., Fan L., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8 5 (2002) 459-465
20. Ozcelik C., Erdmann B., Pilz B., et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA 99 13 (2002) 8880-8885
21. Chu T.F., Rupnick M.A., Kerkela R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370 9604 (2007) 2011-2019
22. Kerkela R., Grazette L., Yacobi R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12 8 (2006) 908-916
23. Khakoo A.Y., Kassiotis C.M., Tannir N., et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 112 11 (2008) 2500-2508
24. Park Y.H., Park H.J., Kim B.S., et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett 243 1 (2006) 16-22
25. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 353 2 (2005) 172-187
26. Thomas D.A., Faderl S., Cortes J., et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103 12 (2004) 4396-4407
27. Yanada M., Takeuchi J., Sugiura I., et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24 3 (2006) 460-466
28. Schermuly R.T., Dony E., Ghofrani H.A., et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115 10 (2005) 2811-2821
29. Gottardi M., Manzato E., and Gherlinzoni F. Imatinib and hyperlipidemia. N Engl J Med 353 25 (2005) 2722-2723
30. Su E.J., Fredriksson L., Geyer M., et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 14 7 (2008) 731-737
31. Deininger M.W., O'Brien S.G., Ford J.M., et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21 8 (2003) 1637-1647
32. Fernandez A., Sanguino A., Peng Z., et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 117 12 (2007) 4044-4054
33. Waning is issued on drug for leukemia. NY Times (2006). Available at: http://www.nytimes.com/2006/07/24/business/24drug.html?_r=1& scp=1&sq=imatinib%20warning&st=cse Accessed December 31, 2008
34. Atallah E., Kantarjian H., and Cortes J. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.'. Nat Med 13 1 (2007) 14 author reply 5-6
35. Gambacorti-Passerini C., Tornaghi L., Franceschino A., et al. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 13 1 (2007) 13-14 author reply 5-6
36. Hatfield A., Owen S., and Pilot P.R. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 13 1 (2007) 13 author reply 5-6
37. Mann D.L. Targeted cancer therapeutics: the heartbreak of success. Nat Med 12 8 (2006) 881-882
38. Verweij J., Casali P.G., Kotasek D., et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumour patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 43 6 (2007) 974-978
39. Atallah E., Durand J.B., Kantarjian H., et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 110 4 (2007) 1233-1237
40. Perik P.J., Rikhof B., de Jong F.A., et al. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. Ann Oncol 19 2 (2008) 359-361
41. Maitland M.L., and Ratain M.J. Terminal ballistics of kinase inhibitors: there are no magic bullets. Ann Intern Med 145 9 (2006) 702-703
42. Rock E.P., Goodman V., Jiang J.X., et al. Food and drug administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12 1 (2007) 107-113
43. Abrams T.J., Murray L.J., Pesenti E., et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2 10 (2003) 1011-1021
44. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 21 (2006) 2516-2524
45. Crul M., Rosing H., de Klerk G.J., et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 38 12 (2002) 1615-1621
46. Dorn II G.W., and Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115 3 (2005) 527-537
47. Benjamin I.J., and Schneider M.D. Learning from failure: congestive heart failure in the postgenomic age. J Clin Invest 115 3 (2005) 495-499
48. Peters E.C., and Gray N.S. Chemical proteomics identifies unanticipated targets of clinical kinase inhibitors. ACS Chem Biol 2 10 (2007) 661-664
49. Chen M.H., Kerkela R., and Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 118 1 (2008) 84-95
50. Fabian M.A., Biggs III W.H., Treiber D.K., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23 3 (2005) 329-336
51. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 12 (2005) e154-e235
52. Ewer M.S., Lenihan D.J., and Khakoo A.Y. Sunitinib-related cardiotoxicity: an interdisciplinary issue. Nat Clin Pract Cardiovasc Med 5 7 (2008) 364-365
53. Cimini M., Fazel S., Zhuo S., et al. c-kit dysfunction impairs myocardial healing after infarction. Circulation 116 11 Suppl (2007) I77-I82
54. Fazel S., Cimini M., Chen L., et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest 116 7 (2006) 1865-1877
55. Fazel SS, Chen L, Angoulvant D, et al. Activation of c-kit is necessary for mobilization of reparative bone marrow progenitor cells in response to cardiac injury. FASEB 2008;22(3):930-40.
56. Zymek P., Bujak M., Chatila K., et al. The role of platelet-derived growth factor signaling in healing myocardial infarcts. J Am Coll Cardiol 48 11 (2006) 2315-2323
57. Andrae J., Gallini R., and Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22 10 (2008) 1276-1312 Review
58. Carmeliet P., Ng Y.S., Nuyens D., et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 5 (1999) 495-502
59. Tammela T., Enholm B., Alitalo K., et al. The biology of vascular endothelial growth factors. Cardiovasc Res 65 3 (2005) 550-563 Review
60. Izumiya Y., Shiojima I., Sato K., et al. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 47 5 (2006) 887-893
61. Shiojima I., Sato K., Izumiya Y., et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115 8 (2005) 2108-2118